Demant in the news

Demant acquired German hearing aid chain Kind for 700 million euros, keeping the brand while integrating its technology and maintaining clinics to boost revenue and margins.

Demant is enhancing the KIND brand in Germany by integrating its own technology to create synergies without major cost-cutting.

Demant faces short-term earnings pressure but has strong medium-term growth prospects driven by product launches and retail expansion.

RBC Capital starts coverage on Demant with a Sector Perform rating, noting strong market position but limited growth and increased risks from recent acquisition.

Demant meets revenue expectations and maintains a cautious growth outlook for 2025 amid slower market expansion.

Impilo is acquiring Oticon Medical from Demant to grow its bone-anchored hearing solutions business independently.

Bernstein lowered Demant's price target to 303 DKK but kept an outperform rating.

Demant's third-quarter growth was mainly supported by its Danish retail segment, while its wholesale hearing aid business and the US private market faced declines.

Demant's forecast is slightly impacted by a weaker commercial market in the USA.

Demant meets revenue expectations and maintains a cautious growth outlook for 2025 amid slower market expansion in hearing healthcare.

Demant's shares rose after Q3 organic growth beat expectations, though profitability missed and guidance was lowered.

Demant reported moderate 3% organic growth in Q3 amid a weak market, maintaining full-year guidance with limited signs of market recovery.

Demant's CEO attributes the company's decline to a weak US market, leading to lower expected growth and profit in 2025.

Demant's Q3 2025 revenue slightly missed forecasts but its stock surged on optimism about the new Oticon Seal hearing aid and strategic growth initiatives, maintaining 2025 guidance amid market challenges.

Short sellers are increasing bets against Demant and Genmab while reducing positions in Pandora, indicating changing market sentiment.

Demant's Q3 revenue was slightly below expectations due to weaker growth in hearing aid sales.

Demant A/S saw a significant drop in short interest in October, trades near $18.67, and operates in hearing healthcare technology.

Demant is selling its hearing implant subsidiary Oticon Medical for up to 600 million DKK, expecting a 200 million DKK loss in 2025 due to transition costs, while supporting the handover and aiming to improve liquidity.